R
Rongcheng Luo
Researcher at Southern Medical University
Publications - 12
Citations - 5326
Rongcheng Luo is an academic researcher from Southern Medical University. The author has contributed to research in topics: Icotinib & Lung cancer. The author has an hindex of 6, co-authored 10 publications receiving 4633 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial
Ye Guo,Mei Shi,An-kui Yang,Jifeng Feng,Xiao-Dong Zhu,Young Jin Choi,Guoqin Hu,Jianji Pan,Chunhong Hu,Rongcheng Luo,Yiping Zhang,Liang Zhou,Ying Cheng,Christian Lüpfert,Junliang Cai,Yuankai Shi +15 more
TL;DR: The purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in Chinese and Korean patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Journal ArticleDOI
China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)
Yuankai Shi,Yan Sun,Cuimin Ding,Ziping Wang,Changli Wang,Zheng Wang,Chong Bai,Chunxue Bai,Jifeng Feng,Xiaoqing Liu,Fang Li,Yue Yang,Yongqian Shu,Milu Wu,Jianxing He,Yiping Zhang,Shucai Zhang,Gongyan Chen,Hong-He Luo,Rongcheng Luo,Caicun Zhou,Yanbin Zhou,Qingsong Pang,Hong Zhao,Qiong Zhao,Aiqin Gu,Yang Ling,Cheng Huang,Baohui Han,Shunchang Jiao,Hong Jiao +30 more
TL;DR: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), thanks to their definite efficacy, mild adverse reaction and convenience for oral use, have broken the bottleneck of traditional chemotherapeutic drugs and become an essential treatment for advanced NSCLC.
Journal ArticleDOI
Renoprotective Effect of a Chinese Herbal Formula, Qidan Dihuang Decoction, on Streptozotocin-Induced Diabetes in Rat
TL;DR: Results indicate that Qidan Dihuang decoction can improve the renal function and inhibit renal fibrosis of DN rat via modulating RAS system.